Samsara Vision Europe

13/03/2025

You might have heard that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) decided to reject a potential treatment for geographic atrophy (GA) or late-stage age-related macular degeneration (AMD). Syfovre (pegcetacoplan) was developed to treat the progression of the disease.

The MHRA was concerned that meaningful benefits for patients in terms of their ability to see and manage daily tasks during the trial periods had not been demonstrated.

It’s unfortunate that this drug has not been approved for patients fighting the progression of GA. For now, the SING IMT®️ continues to be the only surgical solution CE marked and immediately available to support late-stage AMD patients in regaining their vision. The device has helped 300+ patients reconnect with the simple tasks and activities that provide independence and bring joy.

The SING IMT is an intraocular telescope approved for use in patients without previous cataract surgery and 55 years and older in CE Referenced countries and is under investigation in the United States.

Visit our SING IMT ‘On-Demand’ Portal to learn more and find out which hospitals are providing this service in the UK: www.singimt.com Register with the password: SINGIMT.

20/02/2025

This , Samsara Vision would like to remind you that Age-Related Macular Degeneration (AMD) can impact much more than vision, including a person’s mental health. Swipe to learn why patients with AMD are likely to experience depression and anxiety.

While late-stage AMD can cause mental health challenges, patients may be able to find relief with the SING IMT®️. Our innovative intraocular telescope is available to support late-stage AMD patients in regaining their vision. The device has helped 300+ patients reconnect with the simple tasks and activities that provide independence and bring joy.

Contact us to find out which hospitals are providing this service in the EU and visit our SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

11/02/2025

February is , a time to raise awareness around the impact of this debilitating disease that robs people of their central vision.

According to recent research:
➡️Approximately 67 million people in the EU are currently affected by any AMD.
➡️Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050 (1 15% increase).
➡️Incidence of late AMD is estimated to increase from 400,000 per year today to 700,000 per year in 2050.

There is currently no cure for AMD. There are pharmaceutical options that slow the progression of the disease (mainly in wet late-stage AMD), but these options come with a high treatment burden for the patients. The SING IMT®️ is the only surgical solution available in Europe to allow patients to regain their central vision.

Visit the SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

Data source: https://pubmed.ncbi.nlm.nih.gov/31712255/

Welcome to the SING IMT™ ON-DEMAND PORTAL. Login now to find the latest content and news about Samsara's SING IMT™

06/02/2025

👏Congratulations to Prof. Dr. med. Marc Schargus for performing the first SING IMT®️ surgery at Asklepios Klinik Nord Heidberg, Hamburg. Samsara Vision is thrilled to welcome another clinic and more German patients to our growing SING IMT®️ community.

The SING IMT®️ is the only device on the market that helps patients living with late-stage macular degeneration regain their central vision and their freedom. The device is available in centers across Germany. To learn more, visit the SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

05/02/2025

Are you alerting your elderly loved ones to technologies that might benefit them, like the SING IMT®?

Samsara Vision’s CEO and President Tom Ruggia explains in this clip that spreading awareness to caregivers is something we’re passionate about at Samsara Vision.

The SING IMT has helped 300+ AMD patients across Europe reconnect with the simple tasks and activities that provide independence and bring joy.

To learn more, visit SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

30/01/2025

According to a recent study, in Germany, the total economic burden of late-stage AMD was estimated to range between €1.4 billion ($1.6 billion) and €10.10 billion ($11.51 billion).

💶The financial costs incurred due to neovascular AMD (nAMD) and geographic atrophy (GA) were €495.31 million ($546.77 million) and €2.04 billion ($2.32 billion), respectively.

💶In GA, 98% of the total cost incurred due to the loss of productivity resulted from the impact on patients, while the remaining 2% of the cost was attributable to the impact on caregivers.

💶In nAMD, 93% of the total cost attributed to the loss of productivity was due to the impact on patients, with caregivers contributing to the remaining 7% of the cost.

💶Per-annum individual cost incurred due to GA and nAMD was estimated at €19 482 ($22 214) and €20 475 ($23 346), respectively.

The study authors say implementing measures to reduce AMD incidence, delay disease progression, and alleviate humanistic burden may help reduce the economic burden of late-stage AMD.

One such way to alleviate that burden: the SING IMT®️. Samsara Vision’s groundbreaking intraocular telescope is the only device on the market that helps patients living with late-stage macular degeneration regain their central vision and their freedom.

The device is available in centers across Germany. To learn more, visit the SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

13/01/2025

PRESS RELEASE: Samsara Vision is pleased to report positive outcomes in a six-month visual and safety study on the SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope).
SING IMT implantation improved distance and near vision, with a low impact on the corneal endothelium cell density and manageable safety outcomes.

Study highlights include:
✅The percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1%
✅Near visual acuity also significantly improved by ⁓3 lines.
✅No clinically meaningful change from baseline in intraocular pressure or anterior chamber depth (ACD).
✅No new complications occurred between the 3- and 6-month follow-ups.

The SING IMT is an intraocular telescope approved for use in patients without previous cataract surgery and 55 years and older in CE Referenced countries and is under investigation in the United States.

https://www.businesswire.com/news/home/20250112004584/en/Samsara-Vision-Announces-Positive-Six-Month-Visual-and-Safety-Outcomes-from-the-SING-IMT%C2%AE-Smaller-Incision-New-Generation-Implantable-Miniature-Telescope

30/12/2024

2024 was a productive year for the SING IMT ®️ community, and the Samsara Vision team is incredibly grateful for the dedicated surgeons who have helped bring hope to late-stage AMD patients. We are proud to share this recap, featuring many of the new centers, new surgeons, and successful surgeries that took place this year. 🎉

02/12/2024

Welcome Klinikum Fulda team to the SING IMT® community.
🟪 Lead surgeon Dr. med. Markus Ladewig, and his team:
🟪 Dr. med. Jan Markus Göbel
🟪 Dr. Iva Ruth Bartmann
🟪 Elvira Wager
🟪 Alexander Brockmann

They were joined by Samsara team members Alexander Hammen-Herold and Dr. Konstantinos Kakoulidis, MD, PhD, FEBO.

Here is another example helping more German patients with late-stage AMD by implanting Samsara Vision’s new intraocular telescope (IOT). SING IMT®, allows patients to regain their central vision and their freedom.

19/11/2024

Help us celebrate Mrs. Luciana, the patient in this clip, who shares her experience regaining her independence with the SING IMT®️.

At Samsara Vision, we celebrate our patients every step of the way. We cheer them on as they go into surgery, and after when they start working with our trained optometrists and occupational therapists to learn how to use their new vision.

Our groundbreaking intraocular telescope, SING IMT, helps late-stage AMD patients regain their central vision and returns their independence.

Visit our SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

13/11/2024

⭕ Independence.
⭕ The ability to do simple tasks they could once do.
⭕ An improved quality of life.

These are the main things that late-stage AMD patients want more than anything.

Watch this clip to hear a late-stage AMD patient talk about her goals for the SING IMT®️ surgery.

At Samsara Vision, our innovative technology provides a treatment option that helps late-stage AMD patients regain their independence and get their life back.

Visit our SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com

11/11/2024

📽️ How does late-stage AMD impact daily life? In this clip, Samsara Vision patient Mrs. Luciana discusses her daily challenges.

The good news? There is hope for Mrs. Luciana and other late-stage AMD patients. The SING IMT®️ helps support late-stage AMD patients in regaining their vision so they can be independent and enjoy life again.

Visit our SING IMT ‘On-Demand’ Portal with the password: SINGIMT. Register here: www.singimt.com